Novartis and the Bill & Melinda Gates Foundation have announced plans to work together to develop an in vivo gene therapy for sickle cell disease, one of the oldest known and most common genetic disorders. The project will pool the Swiss company’s drug discovery expertise with the Gates Foundation’s charitable healthcare mission. A therapy developed by the collaboration would be distributed to low and middle-income countries.
